



HHS Public Access

Author manuscript

Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2017 February 01.

Published in final edited form as:

Cancer Epidemiol Biomarkers Prev. 2016 February ; 25(2): 264–273. doi:
10.1158/1055-9965.EPI-15-0756.

Impact of treatment and insurance on socioeconomic disparities in survival after adolescent and young adult Hodgkin lymphoma: A population-based study

Theresa H.M. Keegan¹, Mindy C. DeRouen², Helen M. Parsons⁴, Christina A. Clarke^{2,3},
Debbie Goldberg², Christopher R. Flowers⁵, and Sally L. Glaser^{2,3}

¹Department of Internal Medicine, Division of Hematology and Oncology, University of California Davis School of Medicine, Sacramento, CA

²Cancer Prevention Institute of California, Fremont, CA

³Department of Health Research and Policy (Epidemiology), Stanford University School of Medicine, Stanford, CA

⁴Department of Epidemiology and Biostatistics, The University of Texas Health Science Center at San Antonio, San Antonio, TX

⁵Department of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, GA

Abstract

Background—Previous studies documented racial/ethnic and socioeconomic disparities in survival after Hodgkin lymphoma (HL) among adolescents and young adults (AYAs), but did not consider the influence of combined-modality treatment and health insurance.

Methods—Data for 9,353 AYA patients aged 15–39 when diagnosed with HL during 1988–2011 were obtained from the California Cancer Registry. Using multivariate Cox proportional hazards regression, we examined the impact of socio-demographic characteristics (race/ethnicity, neighborhood socioeconomic status (SES), and health insurance), initial combined-modality treatment, and subsequent cancers on survival.

Results—Over the 24-year study period, we observed improvements in HL-specific survival by diagnostic period and differences in survival by race/ethnicity, neighborhood SES and health insurance for a subset of more recently diagnosed patients (2001–2011). In multivariable analyses, HL-specific survival was worse for Blacks than Whites with early-stage (Hazard Ratio (HR): 1.68; 95% Confidence Interval (CI): 1.14, 2.49) and late-stage disease (HR: 1.68; 95% CI: 1.17, 2.41) and for Hispanics than Whites with late-stage disease (HR: 1.58; 95% CI: 1.22, 2.04). AYAs diagnosed with early-stage disease experienced worse survival if they also resided in lower SES neighborhoods (HR: 2.06; 95% CI: 1.59, 2.68). Furthermore, more recently diagnosed AYAs with

Corresponding author: Theresa Keegan, Division of Hematology and Oncology, UC Davis Comprehensive Cancer Center, 4501 X Street, Suite 3016, Sacramento, CA 95817, tkeegan@ucdavis.edu.

Conflicts of interest: There are no other financial disclosures or conflicts of interest to report.

public health insurance or who were uninsured experienced worse HL-specific survival (HR: 2.08; 95% CI: 1.52, 2.84).

Conclusion—Our findings identify several subgroups of HL patients at higher risk for HL mortality.

Impact—Identifying and reducing barriers to recommended treatment and surveillance in these AYAs at much higher risk of mortality is essential to ameliorating these survival disparities.

Keywords

Hodgkin lymphoma; insurance; adolescent; race/ethnicity; survival

Introduction

For Hodgkin lymphoma (HL), one of the most common cancers of adolescents and young adults (AYAs) 15 to 39 years of age (1), treatment with combined-modality (radiation plus chemotherapy) regimens has led to substantial improvements in survival over time and has been commonly recommended for patients with limited stage disease and those with bulky, advanced stage disease (2, 3). However, these impressive survival gains have not been shared uniformly across the AYA population, as worse outcomes have been documented for 15–44 year-olds of lower neighborhood socioeconomic status (SES) (4) and non-White race/ethnicity (4, 5).

Among explanations for these disparities, the similarity of disparities for overall and HL-specific survival (4) and the persistent difference in relative survival by neighborhood SES over time (4), implicate variations in initial treatment and management more than variations in the late complications sometimes resulting from HL (6). We previously found that Blacks (52%) and Hispanics (47%) were more likely to receive chemotherapy alone (as compared with combined-modality) than non-Hispanic Whites (38%) or Asian/Pacific Islanders (APIs) (40%) 15–44 years of age (4). Recent (1995–2010) population-based data on AYAs with early-stage HL also showed that Blacks and Hispanics, and patients residing in lower SES neighborhoods had lower utilization of radiation therapy, and Blacks and Hispanics, and AYAs not receiving radiation had higher mortality (7).

In addition, inadequate health insurance is associated with later stage at diagnosis, under-treatment and worse survival (8–12). Adult (18 years) HL patients with early stage disease who were uninsured were less likely to receive chemotherapy and radiation (12), and AYAs who were uninsured, had public health insurance or resided in lower SES neighborhoods were more likely to be diagnosed with advanced-stage HL (11).

In efforts to date to understand HL survival disparities, no prior studies have considered the influence of both receipt of initial combined-modality treatment and insurance on the racial/ethnic and socioeconomic disparities in survival among AYAs diagnosed with all stages of HL. Therefore, to identify socio-demographic patient subgroups that have not benefited from well-established and effective treatments, we evaluated the impact of socio-demographic characteristics (race/ethnicity, neighborhood SES and health insurance), initial

combined-modality treatment, and subsequent cancers on survival among AYAs diagnosed with early and late stage HL.

Materials and Methods

Patients

Patients eligible for the study were all persons who resided in California when newly diagnosed at ages 15 through 39 years with classical HL (International Classification of Diseases—Oncology, 3rd edition (13) morphology codes 9650–9655, 9663–9667) during the period January 1, 1988 through December 31, 2011 and reported to the California Cancer Registry (CCR). From the CCR, which operates under a state cancer reporting law and comprises three National Cancer Institute (NCI) Surveillance, Epidemiology and End Results (SEER) registries, we obtained information routinely recorded in the medical record at diagnosis for each patient on age, sex, race/ethnicity (non-Hispanic White (hereafter called “White”), Hispanic, Black, and API), summary stage (localized (Ann Arbor stage I), regional (stage II), advanced (stage III/IV)), extent of disease, tumor histologic subtype (nodular sclerosis, mixed cellularity, lymphocyte depletion, lymphocyte rich, or not otherwise specified), marital status (never married, married, previously married, unknown), hospital providing initial care, and census-block group of residence. With information on extent of disease, we classified patients by the presence of B symptoms (weight loss, night sweats, and fever) and human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS). In addition, we obtained registry data on initial treatment modality (radiation (yes, no, unknown) and chemotherapy (yes, no, unknown)), from which we created a combined modality measure; subsequent primary cancer(s) reported during the study period; vital status (routinely determined by the CCR through hospital follow-up and linkages to state and national vital status and other databases) as of December 2012; and, for the deceased, the underlying cause of death as routinely coded by state vital statistics personnel.

We also obtained information on the primary source of payment at initial diagnosis and/or treatment (health insurance), which was reportable to the CCR for patients diagnosed from 2001 forward. Health insurance was grouped into public (Medicaid and other government-assisted programs), private (health maintenance organizations, preferred provider organizations, managed care not otherwise specified, and military care), none and unknown (11). Consistent with prior observations that the small percentage of AYA cancer patients who were uninsured likely reflect retroactive enrollment in Medicaid at the time of cancer diagnosis (9), we considered publicly insured and uninsured together in the survival analyses. Hospitals were classified according to whether or not they were NCI-designated cancer centers.

We used a multi-component index of neighborhood SES based on patients’ residential census-block group at diagnosis. The index is derived from data from the 2000 U.S. Census (for cases diagnosed through 2005) and the 2006–2010 American Community Survey (for cases diagnosed in 2006 forward) on education, occupation, unemployment, household income, poverty, rent, and house values (14). The indices are grouped into quintiles, based on the distribution of SES across all census block groups in California, and, as done

previously (4), into one of two categories for models stratified by stage at diagnosis: lower SES (quintiles 1, 2 and 3) and higher SES (quintiles 4 and 5). Each cancer case was assigned to his/her neighborhood SES category. Based upon the population density of census blocks (15, 16), we defined urbanization level as metropolitan (metropolitan urban and metropolitan suburban blocks), non-metropolitan (city, town and rural blocks) or unknown.

The final study population included 9,353 AYA HL patients after exclusion, in a hierarchical manner, of those with: 1) unknown race/ethnicity (n=166); 2) cancer registry or death certificate evidence of HIV or AIDS (17) (n=262), because of the substantially poorer outcome of HIV-associated HL during the study period (18, 19); 3) HL diagnosis at autopsy only, by death certificate only, or with zero/invalid survival time (n=40). All study protocols were overseen by the Institutional Review Board of the Cancer Prevention Institute of California.

Statistical analyses

Outcomes of interest included overall survival, which considers death from all causes, and HL-specific survival, which considers only death from HL. For deceased patients, survival time was measured in days from the date of diagnosis to the date of death from any cause for overall survival, and to the date of death from HL for HL-specific survival. Patients who died from other causes were censored at the time of death in analyses of HL-specific survival. Patients alive at the study end date (12/31/2012) were censored at this time or at the date of last known contact. Ninety-four percent of censored patients had a follow-up date within two years of the study end date but this number was slightly higher for Whites (95%), Blacks (96%), and APIs (95%) than for Hispanics (89%).

To evaluate associations with survival (overall and HL-specific) controlling for known prognostic factors, we used multivariable Cox proportional hazards regression to estimate hazard ratios (HRs) and associated 95% confidence intervals (CIs). Models included variables with *a priori* reasons for inclusion (e.g., age, race/ethnicity, gender, year of diagnosis, marital status, B symptoms, histologic subtype, hospital type, neighborhood SES and urbanization, and insurance status) and included stage at diagnosis, combined-modality therapy, and subsequent cancer as stratifying variables to allow for differing baseline hazards associated with these variables. Additionally, separate Cox proportional hazards models were conducted by stage at diagnosis. Effect modification was assessed between SES and stage at diagnosis, health insurance, and gender; between race/ethnicity and SES, health insurance, and stage at diagnosis; and between age and marital status, by including interaction terms in the multivariable models. No interaction terms were statistically significant at $p < 0.05$. In all models, the proportional hazards assumption was assessed numerically based on cumulative sums of Martingale residuals (20) and visually based on inspection of the survival curves (log (-log) of the survival distribution function by log (months)). There was evidence of a violation of this assumption with stage at diagnosis, combined-modality therapy and subsequent cancers; therefore, stratified Cox proportional hazards regression models are presented. Regression analyses were conducted using SAS version 9.3 software (SAS institute Inc., Cary, NC, USA).

Results

In this cohort of 9,353 AYA HL patients, 32% were followed for 15 years or more, with the mean follow-up time of 11.0 years (std=7.1). Socio-demographic and clinical characteristics of AYA HL patients varied by race/ethnicity, with a predominance of Whites (63%) and, to a lesser extent, Hispanics (24%), and an increasing proportion of Asians over time (Table 1). Black (40%) and Hispanic (37%) AYAs were more likely to be diagnosed at an advanced stage than Whites (31%) or APIs (34%), and higher percentages of Black (54%) and Hispanic (49%) AYAs received chemotherapy alone than Whites (40%) or APIs (42%). More than 73% of Blacks and Hispanics resided in the lowest three categories of neighborhood SES compared to fewer than 47% of Whites and APIs. Blacks (35%) and Hispanics (39%) were much more likely to have public or no insurance than Whites (17%) or APIs (16%). Nearly 6% of AYA HL patients were diagnosed with a subsequent primary cancer. As of December 2012, more than 13% of AYA HL patients had died, predominantly from cancer (72%).

In multivariable analyses, worse HL-specific survival was associated with male sex (borderline significance), earlier year of diagnosis, and presence of B symptoms (Table 2). Black AYAs experienced a 62% higher risk of HL death (hereafter referred to as mortality) (HR: 1.62; 95% CI: 1.24, 2.11) and Hispanics experienced a 35% higher risk of HL mortality (HR: 1.35; 95% CI: 1.12, 1.64) than Whites. In addition, AYAs residing in lower SES neighborhoods experienced a 52% to 77% greater risk of HL mortality than those residing in the highest SES neighborhood categories. Worse overall survival (Table 2) was associated with many of the same factors as HL-specific survival, except that earlier age at diagnosis was associated with better all-cause survival.

AYAs with public or no insurance experienced much worse HL-specific survival (HR: 2.08; 95% CI: 1.52, 2.84) than those with private or military insurance (Table 2). The addition of health insurance to the multivariable models attenuated the hazard ratios for race/ethnicity by less than 9%, but attenuated the hazard ratios for neighborhood SES by up to 22%. Nevertheless, the hazard ratio for HL-specific survival comparing the highest neighborhood SES to the lowest was still evident, although of borderline significance (HR: 1.67; 95% CI: 0.97, 2.86; data not shown in tables).

In separate models for stage at diagnosis (Table 3), Blacks with early- and late-stage disease experienced a 68% greater risk of HL mortality, while Hispanics with late-stage, but not early-stage, disease experienced a greater risk of HL mortality (HR: 1.58; 95% CI: 1.22, 2.04). In addition, the association between lower neighborhood SES and HL-specific survival only was apparent among AYAs diagnosed with early-stage disease (HR: 2.06; 95% CI: 1.59, 2.68). AYAs with early or late-stage disease experienced greater than a two-fold increased risk of HL mortality if they had public or no insurance. Worse overall survival by stage at diagnosis (Table 3) was associated with many of the same factors as HL-specific survival.

The use of radiation in HL treatment decreased over time (Figure 1). To compare our results to those in prior studies (7, 12), we also examined the impact of initial combined-modality

therapy on survival as an adjustment variable (rather than a stratifying variable due the violation of the proportional hazards assumption). We found that initial treatment with radiation was associated with better HL-specific survival (HR for chemotherapy and radiation (vs. chemotherapy only): 0.85; 95% CI: 0.71, 1.02; HR for radiation only (vs. chemotherapy only): 0.34; 95% CI: 0.23, 0.51; data not shown in tables). These associations were similar for early- and late-stage disease (Figure 2).

Discussion

In this population-based study of more than 9,000 AYAs diagnosed with HL over a 24-year period, we observed improvements in survival over time, but also striking disparities in survival by race/ethnicity, neighborhood SES and health insurance for a subset of more recently diagnosed patients. In particular, Blacks (regardless of disease stage) and Hispanics with late-stage disease experienced worse survival than Whites. In addition, AYAs diagnosed with early-stage disease experienced worse survival if they also resided in lower SES neighborhoods. Furthermore, more recently diagnosed AYAs with public health insurance or no insurance experienced greater than a two-fold increased risk of HL mortality. Together, these findings identify vulnerable subgroups of HL patients at higher risk for HL mortality and point to disparities in treatment delivery and follow-up care as likely contributing factors.

Our previous work in outcomes for young adult HL patients suggested that survival disparities by race/ethnicity or neighborhood SES may be due to variations in initial treatment and management (4). Consistent with studies that found initial treatment to vary by race/ethnicity (4, 7), neighborhood SES (7), and health insurance (12), we also observed that Blacks and Hispanics, AYAs residing in lower SES neighborhoods, and AYAs with public or no insurance were more likely to receive chemotherapy alone as initial treatment. Our group and others (7, 12) also found that these disparities in treatment were associated with worse survival. Despite the survival benefits of radiation, this therapy has been associated with subsequent primary malignancies (6, 7, 21), an outcome that we were able to consider in our analyses. Specifically, we found that a somewhat higher proportion of patients who received radiation for their HL had subsequent cancer (4.9% versus 6.9%), which was associated with worse overall survival (data not shown); modern treatments with lower doses of radiation (7) may result in fewer subsequent cancers (21) and should continue to be monitored. However, even after controlling for initial treatment and subsequent cancers, we still observed differences in survival by race/ethnicity, neighborhood SES and health insurance, suggesting that other factors are influencing these associations.

Expanding on a prior study that found AYA HL patients who were uninsured or had public health insurance were more likely to be diagnosed with advanced-stage HL (11), we found that AYA HL patients with these types of insurance experienced worse HL-specific survival, whether they had early- or late-stage disease. In studies of AYA cancer survivors, health insurance rates have been found to decrease with time from diagnosis (22, 23), particularly for older AYAs and those with less education (23), and a lack of health insurance is a barrier to receiving any medical care (22, 24). Further, more than two-thirds of uninsured survivors have been found to have no personal provider or routine medical care and, even with health

insurance, AYA cancer survivors are more likely to forgo medical care due to costs (24). Collectively, these results suggest that health insurance is a critical barrier to receiving cancer-related medical care that can impact prognosis. While the implementation of the measures from the Patient Protection and Affordable Care Act (ACA) of 2010 and 2014 (25, 26) should improve AYA cancer survivors' access to health insurance, studies should continue to monitor barriers to health insurance enrollment and medical care in AYAs.

Our findings of worse survival among Blacks and Hispanics and AYAs with HL residing in lower SES neighborhoods are consistent with those of prior studies (4, 7). We observed some differences by stage at diagnosis: the impact of neighborhood SES was stronger for early-stage disease and Hispanics with late-stage disease experienced worse HL survival. Although we did not have health insurance information for AYAs throughout our study period, it is likely that factors beyond health insurance are influencing these race/ethnicity and neighborhood SES associations. Inadequate long-term follow-up in patients could result in a delay in diagnosing and treating complications (27), particularly for AYAs, who tend to lack knowledge about their higher risk for developing complications (28–30). Financial concerns, including lost wages, copayments, high deductibles, childcare and transportation costs (24, 31–33) can be burdensome and influence follow-up care, particularly for AYAs with financial limitations (e.g., debt from college or starting a career). In addition, if poor health behaviors and comorbid conditions are more prevalent in lower-SES and/or non-White HL patients, as found for patients with other cancers (34–38), these factors, too, could increase post-treatment complications and reduce survival.

Our study is subject to some limitations. We considered the first course of treatment, but lacked details (e.g., dosing) on chemotherapy, radiation and other treatment received after this period, and there is the potential for radiation (39, 40) and chemotherapy (40) to be under-ascertained; therefore, our findings could be subject to residual confounding from incomplete treatment data (41). While it is possible that our findings are partially influenced by indication bias (i.e., patients who received radiation alone had more favorable disease characteristics and thus more favorable outcomes), it is also possible that some patients received radiation alone because they had comorbidities that precluded use of chemotherapy. Given that combined-modality therapy was broadly recommended by guidelines across all stages of HL during the study period (2, 3), the most plausible explanation for improved survival among patients who received radiation alone is under-ascertainment of chemotherapy, particularly for patients with advanced-stage disease. We were unable to consider health insurance at diagnosis for patients diagnosed before 2001, and lacked information on changes to health insurance after initial treatment, treatment adherence or quality of care--factors that can influence subsequent care and outcomes. We also were unable to determine if patients were undocumented and ineligible for public health insurance. Because cancer registry data do not include potentially relevant clinical data such as prognostic serum measures (42), International Prognostic Index, or prognostic tumor characteristics (e.g., presence of Epstein-Barr virus in tumor cells (5)), or information on lifestyle behaviors or comorbid conditions, our analyses could not examine the impact of these factors on survival. Our study also lacked individual-level measures of SES to consider separately or with our neighborhood measure. While neighborhood and individual SES are associated, neighborhood SES has been found to underestimate associations

observed with individual-level SES (43). However, our multifaceted measure of neighborhood SES at the block group-level incorporated several domains of education, income, employment, and cost of living that capture various elements of the socioeconomic environment that may augment individual-level SES. Our study may also be subject to potential misclassification of race/ethnicity, although we previously have detected excellent overall agreement with self-reported race/ethnicity for Whites and Blacks, and good agreement for Hispanics and Asians (44, 45).

Despite these limitations, this study was population-based and included a large diverse population of AYA HL cancer patients who received their care across all types of institutions, increasing the generalizability of these findings. In addition, our study is one of the first to consider the influence of initial combined-modality treatment and health insurance on previously noted racial/ethnic and socioeconomic disparities in survival among AYAs diagnosed with early- and late-stage HL.

This study found that AYA HL patients of Black or Hispanic race/ethnicity, those who resided in lower SES neighborhoods, and those who were uninsured or publicly insured experienced worse HL-specific survival. While prior studies have noted these racial/ethnic and SES survival disparities, our study extends these previous efforts by considering combined-modality treatment, subsequent primary cancers and health insurance. With uninsurance rates historically peaking in adolescence and young adulthood (46), AYA HL patients may be particularly vulnerable to failing to receive cancer survivor-focused medical care. The ACA has the potential to influence both access to insurance and use of necessary health care for AYAs and should be evaluated in future studies. In addition, identifying and reducing barriers to recommended treatment and surveillance in these AYAs at higher risk of mortality is essential to ameliorating these survival disparities.

Acknowledgments

Financial support: This work was supported by the Stanford Cancer Institute (T.H.M. Keegan), the Cancer Prevention Institute of California (S.L. Glaser), the National Cancer Institute's Surveillance, Epidemiology and End Results Program under contract HHSN261201000140C awarded to the Cancer Prevention Institute of California (M.C. DeRouen, C.A. Clarke, D. Goldberg), and a National Cancer Institute Career Development Award (H.M. Parsons, K07CA175063). The funders did not have any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.

The collection of cancer incidence data used in this study was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885; the National Cancer Institute's Surveillance, Epidemiology and End Results Program under contract HHSN261201000140C awarded to the Cancer Prevention Institute of California, contract HHSN261201000035C awarded to the University of Southern California, and contract HHSN261201000034C awarded to the Public Health Institute; and the Centers for Disease Control and Prevention's National Program of Cancer Registries, under agreement U58DP003862-01 awarded to the California Department of Public Health. The ideas and opinions expressed herein are those of the author(s) and endorsement by the State of California, Department of Public Health the National Cancer Institute, and the Centers for Disease Control and Prevention or their Contractors and Subcontractors is not intended nor should be inferred.

C.A. Clarke received research funding from Genentech unrelated to the submitted work.

References

1. Howlader, N.; Noone, AM.; Krapcho, M.; Garshell, J.; Miller, D.; Altekruse, SF.; Kosery, CL.; Yu, M.; Ruhl, J.; Tatalovich, Z.; Cho, H.; Mariotto, A.; Lewis, DR.; Chen, HS.; Feuer, EJ.; Cronin, KA., editors. SEER Cancer Statistics Review, 1975–2012. Bethesda, MD: National Cancer Institute; 2015. http://seer.cancer.gov/csr/1975_2012/ based on November 2014 SEER data submission, posted to the SEER web site, April 2015 ed.
2. Das P, Ng A, Constine LS, Advani R, Flowers C, Friedberg J, et al. ACR Appropriateness Criteria(R) on Hodgkin's lymphoma-unfavorable clinical stage I and II. *J Am Coll Radiol.* 2011; 8:302–308. [PubMed: 21531305]
3. Terezakis SA, Metzger ML, Hodgson DC, Schwartz CL, Advani R, Flowers CR, et al. ACR Appropriateness Criteria Pediatric Hodgkin Lymphoma. *Pediatr Blood Cancer.* 2014; 61:1305–1312. [PubMed: 24616347]
4. Keegan TH, Clarke CA, Chang ET, Shema SJ, Glaser SL. Disparities in survival after Hodgkin lymphoma: a population-based study. *Cancer Causes Control.* 2009; 20:1881–1892. [PubMed: 19557531]
5. Keegan TH, Glaser SL, Clarke CA, Gulley ML, Craig FE, Digiuseppe JA, et al. Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma: a population-based study. *J Clin Oncol.* 2005; 23:7604–7613. Epub 2005 Sep 26. [PubMed: 16186595]
6. Jachimowicz RD, Engert A. The challenging aspects of managing adolescents and young adults with Hodgkin's lymphoma. *Acta Haematol.* 2014; 132:274–278. [PubMed: 25228552]
7. Xavier AC, Costa LJ. Changes in the use of radiation therapy for early classical Hodgkin lymphoma in adolescents and young adults: implications for survival and second malignancies. *Leuk Lymphoma.* 2015; 56:2339–2343. [PubMed: 25393805]
8. Aizer AA, Falit B, Mendu ML, Chen MH, Choueiri TK, Hoffman KE, et al. Cancer-specific outcomes among young adults without health insurance. *J Clin Oncol.* 2014; 32:2025–2030. [PubMed: 24888800]
9. Rosenberg AR, Kroon L, Chen L, Li CI, Jones B. Insurance status and risk of cancer mortality among adolescents and young adults. *Cancer.* 2015; 121:1279–1286. [PubMed: 25492559]
10. Robbins AS, Lerro CC, Barr RD. Insurance status and distant-stage disease at diagnosis among adolescent and young adult patients with cancer aged 15 to 39 years: National Cancer Data Base, 2004 through 2010. *Cancer.* 2014; 120:1212–1219. [PubMed: 24474656]
11. Smith EC, Ziogas A, Anton-Culver H. Association between insurance and socioeconomic status and risk of advanced stage Hodgkin lymphoma in adolescents and young adults. *Cancer.* 2012; 118:6179–6187. [PubMed: 22736071]
12. Olszewski AJ, Shrestha R, Castillo JJ. Treatment selection and outcomes in early-stage classical hodgkin lymphoma: analysis of the national cancer data base. *J Clin Oncol.* 2015; 33:625–633. [PubMed: 25584010]
13. Fritz, F.; Percy, C.; Jack, A.; Shanmugaratnan, K.; Sobin, L.; Parkin, DM., et al., editors. International Classification of Diseases for Oncology. Third. Geneva: World Health Organization; 2000.
14. Yost K, Perkins C, Cohen R, Morris C, Wright W. Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. *Cancer Causes Control.* 2001; 12:703–711. [PubMed: 11562110]
15. Reynolds P, Hurley SE, Quach AT, Rosen H, Von Behren J, Hertz A, et al. Regional variations in breast cancer incidence among California women, 1988–1997. *Cancer Causes Control.* 2005; 16:139–150. [PubMed: 15868455]
16. Urayama KY, Von Behren J, Reynolds P, Hertz A, Does M, Buffler PA. Factors associated with residential mobility in children with leukemia: implications for assigning exposures. *Ann Epidemiol.* 2009; 19:834–840. [PubMed: 19364662]
17. Clarke CA, Glaser SL. Population-based surveillance of HIV-associated cancers: utility of cancer registry data. *J Acquir Immune Defic Syndr.* 2004; 36:1083–1091. [PubMed: 15247562]
18. Vaccher E, Spina M, Tirelli U. Clinical aspects and management of Hodgkin's disease and other tumours in HIV-infected individuals. *Eur J Cancer.* 2001; 37:1306–1315. [PubMed: 11423262]

19. Glaser SL, Clarke CA, Gulley ML, Craig FD, DiGiuseppe JA, Dorfman RF, et al. Population-based patterns of human immunodeficiency virus-related Hodgkin lymphoma in the Greater San Francisco Bay Area, 1988–1998. *Cancer*. 2003; 98:300–309. [PubMed: 12872349]
20. Lin DY, Wei LJ, Ying Z. Checking the Cox model with cumulative sums of martingale-based residuals. *Biometrika*. 1993; 80:557–572.
21. LeMieux MH, Solanki AA, Mahmood U, Chmura SJ, Koshy M. Risk of second malignancies in patients with early-stage classical Hodgkin's lymphoma treated in a modern era. *Cancer Med*. 2015; 4:513–518. [PubMed: 25620577]
22. Keegan TH, Tao L, DeRouen MC, Wu XC, Prasad P, Lynch CF, et al. Medical care in adolescents and young adult cancer survivors: what are the biggest access-related barriers? *J Cancer Surviv*. 2014; 8:282–292. [PubMed: 24408440]
23. Parsons HM, Schmidt S, Harlan LC, Kent EE, Lynch CF, Smith AW, et al. Young and uninsured: Insurance patterns of recently diagnosed adolescent and young adult cancer survivors in the AYA HOPE study. *Cancer*. 2014; 120:2352–2360. [PubMed: 24899580]
24. Kirchhoff AC, Lyles CR, Fluchel M, Wright J, Leisenring W. Limitations in health care access and utilization among long-term survivors of adolescent and young adult cancer. *Cancer*. 2012; 118:5964–5972. [PubMed: 23007632]
25. Moy B, Polite BN, Halpern MT, Stranne SK, Winer EP, Wollins DS, et al. American Society of Clinical Oncology policy statement: opportunities in the patient protection and affordable care act to reduce cancer care disparities. *J Clin Oncol*. 2011; 29:3816–3824. [PubMed: 21810680]
26. Wolfson J, Ruccione K, Reaman GH. Health care reform 2010: expected favorable impact on childhood cancer patients and survivors. *Cancer J*. 2010; 16:554–562. [PubMed: 21131785]
27. Soares A, Biasoli I, Scheliga A, Luiz RR, Costa MA, Land M, et al. Socioeconomic inequality and short-term outcome in Hodgkin's lymphoma. *Int J Cancer*. 2007; 120:875–879. [PubMed: 17131320]
28. Green DM. Late effects of treatment for cancer during childhood and adolescence. *Curr Probl Cancer*. 2003; 27:127–142. [PubMed: 12748582]
29. Zeltzer LK, Lu Q, Leisenring W, Tsao JC, Recklitis C, Armstrong G, et al. Psychosocial outcomes and health-related quality of life in adult childhood cancer survivors: a report from the childhood cancer survivor study. *Cancer Epidemiol Biomarkers Prev*. 2008; 17:435–446. [PubMed: 18268128]
30. Casillas J, Kahn KL, Doose M, Landier W, Bhatia S, Hernandez J, et al. Transitioning childhood cancer survivors to adult-centered healthcare: insights from parents, adolescent, and young adult survivors. *Psychooncology*. 2010; 19:982–990. [PubMed: 20017115]
31. Brown, ML.; Yabroff, KR. Economic impact of cancer in the United States. In: Schottenfeld, DFJJ., editor. *Cancer Epidemiology and Prevention*. 3rd. New York, NY: Oxford Univ; 2006. p. 202-214.
32. Gruber J, Perry I. Will the Affordable Care Act make health insurance affordable? *Issue Brief (Commonw Fund)*. 2011; 2:1–15. [PubMed: 21539012]
33. Nicholson JL, Collins SR. Young, uninsured, and seeking change: health coverage of young adults and their views on health reform. Findings from the Commonwealth fund Survey of Young Adults (2009). *Issue Brief (Commonw Fund)*. 2009; 73:1–22. [PubMed: 20183947]
34. Eversley R, Estrin D, Dibble S, Wardlaw L, Pedrosa M, Favila-Penney W. Post-treatment symptoms among ethnic minority breast cancer survivors. *Oncol Nurs Forum*. 2005; 32:250–256. [PubMed: 15759063]
35. Ahluwalia IB, Mack KA, Murphy W, Mokdad AH, Bales VS. State-specific prevalence of selected chronic disease-related characteristics--Behavioral Risk Factor Surveillance System, 2001. *MMWR Surveill Summ*. 2003; 52:1–80. [PubMed: 14532868]
36. Tammemagi CM, Nerenz D, Neslund-Dudas C, Feldkamp C, Nathanson D. Comorbidity and survival disparities among black and white patients with breast cancer. *Jama*. 2005; 294:1765–1772. [PubMed: 16219879]
37. Woods LM, Rachtel B, Coleman MP. Origins of socio-economic inequalities in cancer survival: a review. *Ann Oncol*. 2006; 17:5–19. Epub 2005 Sep 2. [PubMed: 16143594]

38. Parsons HM, Harlan LC, Seibel NL, Stevens JL, Keegan TH. Clinical trial participation and time to treatment among adolescents and young adults with cancer: does age at diagnosis or insurance make a difference? *J Clin Oncol*. 2011; 29:4045–4053. [PubMed: 21931022]
39. Jagsi R, Abrahamse P, Hawley ST, Graff JJ, Hamilton AS, Katz SJ. Underascertainment of radiotherapy receipt in Surveillance, Epidemiology, and End Results registry data. *Cancer*. 2012; 118:333–341. [PubMed: 21717446]
40. Noone AM, Lund JL, Mariotto A, Cronin K, McNeel T, Deapen D, et al. Comparison of SEER Treatment Data With Medicare Claims. *Med Care*. 2014
41. Giordano SH, Kuo YF, Duan Z, Hortobagyi GN, Freeman J, Goodwin JS. Limits of observational data in determining outcomes from cancer therapy. *Cancer*. 2008; 112:2456–2466. [PubMed: 18428196]
42. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. *N Engl J. Med*. 1998; 339:1506–1514. [PubMed: 9819449]
43. Krieger N. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. *Am J Public Health*. 1992; 82:703–710. [PubMed: 1566949]
44. Clegg LX, Reichman ME, Hankey BF, Miller BA, Lin YD, Johnson NJ, et al. Quality of race, Hispanic ethnicity, and immigrant status in population-based cancer registry data: implications for health disparity studies. *Cancer Causes Control*. 2007; 18:177–187. [PubMed: 17219013]
45. Gomez SL, Glaser SL. Misclassification of race/ethnicity in a population-based cancer registry (United States). *Cancer Causes Control*. 2006; 17:771–781. [PubMed: 16783605]
46. Adams SH, Newacheck PW, Park MJ, Brindis CD, Irwin CE Jr. Health insurance across vulnerable ages: patterns and disparities from adolescence to the early 30s. *Pediatrics*. 2007; 119:e1033–e1039. [PubMed: 17473076]




Figure 1. Percentage (%) of adolescent and young adult Hodgkin lymphoma patients undergoing radiation therapy by year of diagnosis, California, 1988–2011.




Figure 2. Kaplan-Meier curve of Hodgkin lymphoma (HL)-specific survival in adolescent and young adult patients, by combined-modality therapy and stage of disease (stage I/II, stage III/IV), California, 1988–2011. The vertical axis represents survival probability; the horizontal axis represents survival time in years. Combined-modality therapy (dotted black line), radiation therapy only (solid black line), chemotherapy only (dotted grey line), no or unknown therapy (solid grey line).

Table 1

Characteristics of adolescent and young adult Hodgkin lymphoma (HL) patients 15 to 39 years of age at diagnosis (N=9,353) by race/ethnicity, California, 1988–2011.

Characteristics	Race/ethnicity						p-value				
	All patients n=9,353	%	Non-Hispanic White n=5,919	%	Black n=643	%		Hispanic n=2,200	%	Asian/ Pacific Islander n=591	%
Sex											
Male	4,786	51.2	3,029	51.2	316	49.1	1,140	51.8	301	50.9	
Female	4,567	48.8	2,890	48.8	327	50.9	1,060	48.2	290	49.1	0.70
Age at diagnosis (years)											
15–19	1,478	15.8	820	13.9	91	14.2	459	20.9	108	18.3	
20–24	2,224	23.8	1,374	23.2	139	21.6	541	24.6	170	28.8	
25–29	2,201	23.5	1,421	24.0	154	24.0	500	22.7	126	21.3	
30–34	1,937	20.7	1,279	21.6	140	21.8	413	18.8	105	17.8	
30–39	1,513	16.2	1,025	17.3	119	18.5	287	13.0	82	13.9	<0.001
Year of diagnosis											
1988–1992	2,052	21.9	1,528	25.8	135	21.0	317	14.4	72	12.2	
1993–1997	1,865	19.9	1,297	21.9	125	19.4	369	16.8	74	12.5	
1998–2002	1,800	19.2	1,138	19.2	100	15.6	443	20.1	119	20.1	
2003–2006	1,559	16.7	878	14.8	121	18.8	429	19.5	131	22.2	
2007–2011	2,077	22.2	1,078	18.2	162	25.2	642	29.2	195	33.0	<0.001
Marital status at diagnosis											
Married	3,265	34.9	2,147	36.3	161	25.0	753	34.2	204	34.5	
Not married	5,823	62.3	3,622	61.2	458	71.2	1,372	62.4	371	62.8	
Unknown	265	2.8	150	2.5	24	3.7	75	3.4	16	2.7	<0.001
Stage at diagnosis											
I – localized	1,200	12.8	774	13.1	87	13.5	263	12.0	76	12.9	
II – regional	4,507	48.2	2,960	50.0	264	41.1	986	44.8	297	50.3	
III/IV – advanced	3,128	33.4	1,852	31.3	258	40.1	817	37.1	201	34.0	
Missing	518	5.5	333	5.6	34	5.3	134	6.1	17	2.9	<0.001

Characteristics	Race/ethnicity						p-value
	All patients n=9,353	Non-Hispanic White n=5,919	Black n=643	Hispanic n=2,200	Asian/ Pacific Islander n=591	%	
B-symptoms							
No	3,530	2,252	221	800	257	36.4	43.5
Yes	3,343	1,947	254	923	219	42.0	37.1
Missing/Unknown	2,480	1,720	168	477	115	21.7	19.5
Histologic subtype							<0.001
Nodular sclerosis	7,088	4,630	460	1,548	450	70.4	76.1
Mixed cellularity	939	528	78	286	47	13.0	8.0
Lymphocyte depletion	96	53	5	32	6	1.5	1.0
Lymphocyte rich	212	114	26	59	13	2.7	2.2
Not otherwise specified	1,018	594	74	275	75	12.5	12.7
Combined-modality therapy							<0.001
Chemotherapy and radiation	3,421	2,267	171	718	265	32.6	44.8
Chemotherapy only	4,019	2,341	348	1,082	248	49.2	42.0
Radiation only	993	748	52	147	46	6.7	7.8
None/unknown	920	563	72	253	32	11.5	5.4
Subsequent cancer							<0.001
No	8,802	5,542	599	2,105	556	95.7	94.1
Yes*	551	92	14	11	4	4.3	5.9
Breast	121	22.0					
Lymphoma	62	11.3					
Thyroid	48	8.7					
Melanoma	39	7.1					
Acute myeloid leukemia	34	6.2					
Head and neck	28	5.1					
Lung	26	4.7					
Uterus	24	4.4					
Colorectal	22	4.0					
Other Leukemia	22	4.0					

Characteristics	Race/ethnicity						p-value				
	All patients n=9,353	%	Non-Hispanic White n=5,919	%	Black n=643	%		Hispanic n=2,200	%	Asian/ Pacific Islander n=591	%
Soft tissue	17	3.1									
Kidney	13	2.4									
Vulva	11	1.0									
Pancreas	8	1.5									
Acute lymphocytic leukemia	7	1.3									
Anus	6	1.1									
Prostate	6	1.1									
Esophagus	5	0.9									
Testis	5	0.9									
Other	47	8.5									
Received care at an NCI-designated cancer center											
No/Missing	8,312	88.9	5,245	88.6	605	94.1	1,956	88.9	506	85.6	
Yes	1,041	11.1	674	11.4	38	5.9	244	11.1	85	14.4	<0.001
Neighborhood socioeconomic status (quintiles)											
1 (Lowest)	1,310	14.0	431	7.3	177	27.5	660	30.0	42	7.1	
2	1,805	19.3	961	16.2	157	24.4	605	27.5	82	13.9	
3	2,036	21.8	1,349	22.8	141	21.9	420	19.1	126	21.3	
4	2,161	23.1	1,570	26.5	115	17.9	317	14.4	159	26.9	
5 (Highest)	2,041	21.8	1,608	27.2	53	8.2	198	9.0	182	30.8	<0.001
Urbanization level											
Metropolitan	6,130	65.5	3,662	61.9	497	77.3	1,493	67.9	478	80.9	
Non-metropolitan	3,072	32.8	2,173	36.7	133	20.7	662	30.1	104	17.6	
Unknown	151	1.6	84	1.4	13	2.0	45	2.0	9	1.5	<0.001
Health insurance status, limited to patients diagnosed from 2001 to 2011 (n=4,406)											
Private/military insurance	3,113	70.7	1,908	78.2	199	61.6	697	55.5	309	79.4	
Public insurance	881	20.0	335	13.7	97	30.0	391	31.2	58	14.9	
No insurance	200	4.5	75	3.1	16	5.0	103	8.2	6	1.5	
Unknown	212	4.8	121	5.0	11	3.4	64	5.1	16	4.1	<0.001

Characteristics	Race/ethnicity					p-value
	All patients n=9,353	Non-Hispanic White n=5,919	Black n=643	Hispanic n=2,200	Asian/ Pacific Islander n=591	
Vital status						
Alive	8,108	5,148	518	1,910	532	90.0
Death from HL	678	388	72	183	35	5.9
Death from non-Hodgkin lymphoma	113	64	14	29	6	1.0
Death from other cancer	108	80	11	12	5	0.8
Death from heart/cerebrovascular	102	75	5	17	5	0.8
Death from other cause	188	127	18	35	8	1.4
Death from unknown cause	56	37	5	14	0	<0.001

* Data on type of subsequent cancer are presented for all patients only in order to protect confidentiality, as many cancer types included <5 adolescent and young adults when presented by race/ethnicity.

Multivariable hazard ratios (HR) and 95% confidence interval (95% CI) estimates for death from all causes (overall survival) and death from Hodgkin lymphoma (HL-specific survival) in adolescent and young adult HL patients, California, 1988–2011.

Table 2

Characteristic	Overall Survival*		HL-Specific Survival*	
	Deaths	HR (95% CI)	Deaths	HR (95% CI)
Sex				
Female	516	Reference	290	Reference
Male	729	1.31 (1.16, 1.47)	388	1.16 (0.99, 1.35)
Age at diagnosis (years)				
15–19	152	0.59 (0.48, 0.74)	108	0.87 (0.65, 1.16)
20–24	273	0.72 (0.60, 0.86)	155	0.85 (0.66, 1.10)
25–29	281	0.72 (0.61, 0.86)	153	0.87 (0.68, 1.12)
30–34	292	0.93 (0.78, 1.10)	152	1.09 (0.85, 1.39)
35–39	247	Reference	110	Reference
Year of diagnosis				
1988–1992	520	2.42 (1.88, 3.12)	246	2.79 (2.05, 3.80)
1993–1997	317	1.83 (1.43, 2.34)	160	1.73 (1.28, 2.33)
1998–2002	187	1.27 (0.98, 1.65)	118	1.29 (0.95, 1.77)
2003–2006	129	1.15 (0.88, 1.51)	88	1.15 (0.83, 1.59)
2007–2011	92	Reference	66	Reference
Marital status at diagnosis				
Married	453	Reference	223	Reference
Not married	764	1.11 (0.98, 1.26)	434	1.14 (0.95, 1.36)
Unknown	28	0.95 (0.64, 1.41)	21	1.30 (0.82, 2.07)
Race/ethnicity				
Non-Hispanic White	771	Reference	388	Reference
Black	125	1.40 (1.14, 1.71)	72	1.62 (1.24, 2.11)
Hispanic	290	1.16 (1.00, 1.34)	183	1.35 (1.12, 1.64)
Asian/Pacific Islander	59	1.11 (0.85, 1.46)	35	1.21 (0.85, 1.72)
B Symptoms				
No	277	Reference	138	Reference

Characteristic	Overall Survival*			HL-Specific Survival*		
	Deaths	HR	(95% CI)	Deaths	HR	(95% CI)
Yes	499	1.56	(1.34, 1.81)	316	1.87	(1.52, 2.29)
Missing/unknown	469	1.26	(1.07, 1.49)	224	1.42	(1.12, 1.80)
Histologic subtype						
Nodular sclerosis	907	Reference		514	Reference	
Mixed cellularity	153	0.98	(0.82, 1.17)	75	0.86	(0.67, 1.10)
Lymphocyte depletion	21	1.34	(0.86, 2.07)	14	1.41	(0.82, 2.41)
Lymphocyte rich	25	0.88	(0.58, 1.33)	6	0.48	(0.21, 1.08)
Not otherwise specified	139	1.30	(1.08, 1.57)	69	1.06	(0.82, 1.37)
Received care at an NCI-designated cancer center						
No/Missing	1,114	Reference		606	Reference	
Yes	131	0.99	(0.83, 1.20)	72	0.98	(0.76, 1.25)
Neighborhood socioeconomic status, quintiles						
1 (lowest)	243	1.88	(1.53, 2.30)	137	1.77	(1.34, 2.33)
2	278	1.53	(1.26, 1.85)	154	1.52	(1.17, 1.97)
3	278	1.44	(1.20, 1.74)	157	1.54	(1.20, 1.99)
4	250	1.16	(0.96, 1.41)	130	1.17	(0.90, 1.51)
5 (highest)	196	Reference		100	Reference	
Urbanization level						
Metropolitan	809	Reference		436	Reference	
Non-metropolitan	412	1.04	(0.91, 1.17)	225	1.08	(0.91, 1.27)
Unknown	24	1.50	(0.99, 2.27)	17	1.90	(1.15, 3.13)
Health insurance status, limited to patients diagnosed from 2001 to 2011 (n=4,406)*						
Private/military insurance	160	Reference		103	Reference	
Public insurance/ no insurance	125	2.05	(1.58, 2.66)	86	2.08	(1.52, 2.84)
Unknown	13	1.25	(0.70, 2.24)	9	1.25	(0.62, 2.51)

* Stratified by stage at diagnosis, combined modality therapy, and subsequent cancer; adjusted for all variables in the table

Table 3

Multivariable adjusted* hazard ratios (HR) and 95% confidence interval (95% CI) estimates for death from all causes (overall survival) and death from Hodgkin lymphoma (HL-specific survival) in adolescent and young HL patients, by stage at diagnosis, California, 1988–2011.

Characteristic	Stage I/II				Stage III/IV					
	Deaths	Overall Survival*	HL-Specific Survival*	Deaths	HR (95% CI)	Deaths	Overall Survival*	HL-Specific Survival*	Deaths	HR (95% CI)
Sex										
Female	277	Reference	Reference	142	Reference	208	Reference	Reference	134	Reference
Male	318	1.33 (1.12, 1.57)	1.19 (0.94, 1.50)	150	1.19 (0.94, 1.50)	368	1.28 (1.07, 1.52)	221	1.13 (0.90, 1.40)	
Age at diagnosis (years)										
15–19	78	0.67 (0.49, 0.91)	1.15 (0.74, 1.81)	55	1.15 (0.74, 1.81)	67	0.55 (0.40, 0.75)	48	0.68 (0.46, 1.01)	
20–24	132	0.76 (0.58, 0.99)	0.91 (0.60, 1.39)	64	0.91 (0.60, 1.39)	128	0.72 (0.55, 0.93)	86	0.87 (0.62, 1.21)	
25–29	132	0.73 (0.57, 0.95)	0.93 (0.62, 1.41)	62	0.93 (0.62, 1.41)	126	0.72 (0.56, 0.92)	85	0.89 (0.64, 1.23)	
30–34	147	0.94 (0.73, 1.21)	1.32 (0.89, 1.97)	74	1.32 (0.89, 1.97)	130	0.92 (0.72, 1.17)	69	0.91 (0.65, 1.28)	
35–39	106	Reference	Reference	37	Reference	125	Reference	67	Reference	
Year of diagnosis										
1988–1992	250	2.49 (1.70, 3.67)	2.87 (1.79, 4.60)	98	2.87 (1.79, 4.60)	239	2.35 (1.64, 3.37)	135	2.64 (1.72, 4.05)	
1993–1997	160	1.86 (1.28, 2.69)	1.62 (1.03, 2.55)	72	1.62 (1.03, 2.55)	130	1.68 (1.18, 2.39)	75	1.65 (1.08, 2.51)	
1998–2002	89	1.24 (0.84, 1.83)	1.28 (0.80, 2.03)	57	1.28 (0.80, 2.03)	92	1.42 (0.99, 2.04)	60	1.43 (0.93, 2.20)	
2003–2006	56	1.09 (0.72, 1.64)	1.02 (0.62, 1.69)	36	1.02 (0.62, 1.69)	67	1.27 (0.87, 1.85)	50	1.33 (0.85, 2.07)	
2007–2011	40	Reference	Reference	29	Reference	48	Reference	35	Reference	
Marital status at diagnosis										
Married	221	Reference	Reference	92	Reference	210	Reference	122	Reference	
Not married	364	1.16 (0.97, 1.40)	1.31 (0.99, 1.72)	193	1.31 (0.99, 1.72)	358	1.02 (0.85, 1.23)	227	1.01 (0.80, 1.29)	
Unknown	10	1.07 (0.57, 2.04)	1.57 (0.72, 3.42)	7	1.57 (0.72, 3.42)	8	0.56 (0.27, 1.14)	6	0.68 (0.29, 1.57)	
Race/ethnicity										
Non-Hispanic White	391	Reference	Reference	177	Reference	335	Reference	192	Reference	
Black	56	1.39 (1.04, 1.86)	1.68 (1.14, 2.49)	31	1.68 (1.14, 2.49)	62	1.55 (1.17, 2.06)	38	1.68 (1.17, 2.41)	
Hispanic	120	1.04 (0.84, 1.29)	1.10 (0.82, 1.48)	68	1.10 (0.82, 1.48)	148	1.31 (1.07, 1.62)	106	1.58 (1.22, 2.04)	
Asian/Pacific Islander	28	1.09 (0.74, 1.61)	1.22 (0.72, 2.05)	16	1.22 (0.72, 2.05)	31	1.19 (0.82, 1.74)	19	1.22 (0.76, 1.97)	

Characteristic	Stage III/IV					
	Stage III			Stage IV		
	Deaths	Overall Survival* HR (95% CI)	Deaths	HL-Specific Survival* HR (95% CI)	Deaths	HL-Specific Survival* HR (95% CI)
B Symptoms						
No	183	Reference	90	Reference	90	Reference
Yes	208	1.66 (1.35, 2.03)	121	1.89 (1.44, 2.50)	282	1.54 (1.21, 1.97)
Missing/unknown	204	1.08 (0.86, 1.35)	81	1.07 (0.76, 1.50)	204	1.50 (1.14, 1.97)
Histologic subtype						
Nodular sclerosis	472	Reference	242	Reference	390	Reference
Mixed cellularity	56	0.83 (0.63, 1.10)	24	0.76 (0.50, 1.17)	89	1.07 (0.84, 1.35)
Lymphocyte depletion	6	1.23 (0.55, 2.77)	<5	~	13	1.40 (0.80, 2.45)
Lymphocyte rich	17	0.92 (0.55, 1.51)	<5	~	8	1.07 (0.53, 2.18)
Not otherwise specified	44	1.06 (0.77, 1.45)	20	0.87 (0.55, 1.38)	76	1.47 (1.14, 1.89)
Received care at an NCI-designated cancer center						
No/Missing	536	Reference	265	Reference	511	Reference
Yes	59	1.02 (0.78, 1.35)	27	0.94 (0.63, 1.41)	65	0.94 (0.72, 1.22)
Neighborhood socioeconomic status						
Low (Quintiles 1–3)	389	1.77 (1.48, 2.11)	204	2.06 (1.59, 2.68)	366	1.20 (1.00, 1.44)
High (Quintile 4–5)	206	Reference	88	Reference	210	Reference
Urbanization level						
Metropolitan	374	Reference	179	Reference	385	Reference
Non-metropolitan	212	1.10 (0.93, 1.31)	106	1.12 (0.87, 1.44)	178	1.04 (0.86, 1.24)
Unknown	9	1.32 (0.68, 2.59)	7	1.97 (0.91, 4.25)	13	2.01 (1.14, 3.55)
Health insurance status, limited to patients diagnosed from 2001 to 2011 (n=4,406)*						
Private/military insurance	78	Reference	50	Reference	75	Reference
Public insurance/ no insurance	53	2.19 (1.49, 3.21)	37	2.07 (1.30, 3.30)	69	2.09 (1.46, 2.99)
Unknown	5	1.05 (0.42, 2.64)	<5	~	6	1.36 (0.58, 3.20)

* Stratified by combined modality therapy and subsequent cancer; adjusted for all variables in the table

~ Data not shown